Document is current
Any future updates will be listed below
-
Authors
Hamo, Carine E. https://orcid.org/0000-0002-7063-1727
DeJong, Colette
Hartshorne-Evans, Nick https://orcid.org/0000-0003-0356-1471
Lund, Lars H.
Shah, Sanjiv J. https://orcid.org/0000-0002-5655-8201
Solomon, Scott
Lam, Carolyn S. P. https://orcid.org/0000-0003-1903-0018
- License Information
-
More Information
Article History
Accepted: 15 July 2024
First Online: 14 August 2024
Competing interests
: C.D.’s spouse is employed by and holds stock in iRhythm Technologies. L.H.L. is supported by Karolinska Institutet, the Swedish Research Council (grant 523-2014-2336), the Swedish Heart Lung Foundation (grants 20150557, 20190310) and the Stockholm County Council (grants 20170112, 20190525). L.H.L. is advisor/consultant for AstraZeneca, Novartis, Bayer, Vifor Pharma, Pharmacosmos, Merck/MSD, Respicardia, and Medscape; receives honoraria/lecture fees from AstraZeneca, Novartis, Vifor Pharma, Bayer, Medscape and Radcliffe Cardiology; receives research grants from AstraZeneca, Novartis, Boehringer Ingelheim, Vifor Pharma and Pharmacosmos; and has stock ownership for AnaCardio. S.J.S. is supported by research grants from the U.S. National Institutes of Health (U54 HL160273; R01 HL140731; and R01 HL149423); has received research funding from AstraZeneca, Corvia and Pfizer; and has received consulting fees from Abbott, Alleviant, Amgen, Aria CV, AstraZeneca, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, BridgeBio, Bristol Myers Squibb, Corvia, Cytokinetics, Edwards Lifesciences, Eidos, Imara, Impulse Dynamics, Intellia, Ionis, Lilly, Merck, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sardocor, Shifamed, Tenax, Tenaya and Ultromics. S.S. has received research grants from Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/Bridgebio, Gossamer, GSK, Ionis, Lilly, National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, and US2.AI and has consulted for Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, CPC Clinical Research, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc., Quidel Corporation, Radcliffe Group Ltd., Recardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. The remaining authors declare no competing interests.
